Diagnostic Microbiology & Infectious Disease
Volume 54, Issue 1 , Pages 13-21 , January 2006

Analysis of Salmonella spp. with resistance to extended-spectrum cephalosporins and fluoroquinolones isolated in North America and Latin America: report from the SENTRY Antimicrobial Surveillance Program (1997–2004)

  • Douglas J. Biedenbach

      Affiliations

    • JMI Laboratories, 345 Beaver Kreek Centre, Suite A, North Liberty, IA 52317, USA
    • Corresponding Author InformationCorresponding author. Tel.: +1-319-665-3370; fax: +1-319-665-3371.
    • ,
  • Mark Toleman

      Affiliations

    • BCARE, Department of Pathology and Microbiology, School of Medicine University of Bristol, Bristol, BS8 1TD UK
    • ,
  • Timothy R. Walsh

      Affiliations

    • BCARE, Department of Pathology and Microbiology, School of Medicine University of Bristol, Bristol, BS8 1TD UK
    • ,
  • Ronald N. Jones

      Affiliations

    • JMI Laboratories, 345 Beaver Kreek Centre, Suite A, North Liberty, IA 52317, USA

Received 16 June 2005 ,Accepted 16 June 2005.

References 

  1. Aarestrup FM, Wiuff C, Molbak K, Threlfall EJ. Letters to the Editor. Is it time to change fluoroquinolone breakpoints for Salmonella spp.?. Antimicrob. Agents. Chemother. 2003;47:827–829
  2. AitMhand R, Soukri A, Moustaoui N, Amarouch H, ElMdaghri N, Sirot D, et al. Plasmid-mediated TEM-3 extended-spectrum β-lactamase production in Salmonella typhimurium in Casablanca. J. Antimicrob. Chemother. 2002;49:169–172
  3. Albayrak F, Cokca F, Erdem B, Aysev AD. Predictive value of nalidixic acid resistance for detecting salmonellae with decreased ciprofloxacin susceptibility. Int. J. Antimicrob. Agents. 2004;23:332–336
  4. Alvarez M, Tran JH, Chow N, Jacoby GA. Epidemiology of conjugative plasmid-mediated AmpC β-lactamases in the United States. Antimicrob. Agents Chemother. 2004;48:533–537
  5. Baraniak A, Sadowy E, Hryniewicz W, Gniadkowski M. Two different extended-spectrum β-lactamases (ESBLs) in one of the first ESBL-producing salmonella isolates in Poland. J. Clin. Microbiol. 2002;40:1095–1097
  6. Carattoli A, Tosini F, Giles WP, Rupp ME, Hinrichs SH, Angulo FJ, et al. Characterization of plasmids carrying CMY-2 from expanded-spectrum cephalosporin-resistant Salmonella strains isolated in the United States between 1996 and 1998. Antimicrob. Agents Chemother. 2002;46:1269–1272
  7. Casin I, Breuil J, Darchis JP, Guelpa C, Collatz E. Fluoroquinolone resistance linked to GyrA, GyrB, and ParC mutations in Salmonella enterica Typhimurium isolates in humans. Emerg. Infect. Dis. 2003;9:1455–1457
  8. Clinical and Laboratory Standards Institute . Performance standard for antimicrobial susceptibility testing. Document M100-S15. Wayne (PA): CLSI; 2005;
  9. Cormican M, Butler C, Morris D, Corbett-Feeney G, Flynn J. Antibiotic resistance amongst Salmonella enterica species isolated in the Republic of Ireland. J. Antimicrob. Chemother. 1998;42:116–118
  10. Crump JA, Barrett TJ, Nelson JT, Angulo FJ. Reevaluating fluoroquinolone breakpoints for Salmonella enterica serotype Typhi and for non-typhi salmonellae. Clin. Infect. Dis. 2003;37:75–81
  11. Edelstein M, Pimkin M, Dmitrachenko T, Semenov V, Kozlova N, Gladin D, et al. Multiple outbreaks of nosocomial salmonellosis in Russia and Belarus caused by a single clone of Salmonella enterica serovar Typhimurium producing an extended-spectrum β-lactamase. Antimicrob. Agents Chemother. 2004;48:2808–2815
  12. Fey PD, Safranek TR, Rupp ME, Dunne EF, Ribot E, Iwen PC, et al. Ceftriaxone-resistant salmonella infection acquired by a child from cattle. N. Engl. J. Med. 2000;342:1242–1249
  13. Giraud E, Cloeckaert A, Kerboeuf D, Chaslus-Dancla E. Evidence for active efflux as the primary mechanism of resistance to ciprofloxacin in Salmonella enterica serovar Typhimurium. Antimicrob. Agents Chemother. 2000;44:1223–1228
  14. Guerra B, Malorny B, Schroeter A, Helmuth R. Letter to the editor. Multiple resistance mechanisms in fluoroquinolone-resistant Salmonella isolates from Germany. Antimicrob. Agents Chemother. 2003;47:2059
  15. Hakanen A, Kotilainen P, Jalava J, Siitonen A, Huovinen P. Detection of decreased fluoroquinolone susceptibility in salmonellas and validation of nalidixic acid screening test. J. Clin. Microbiol. 1999;37:2577–3572
  16. Hakanen A, Kotilainen P, Huovinen P, Helenius H, Siitonen A. Reduced fluoroquinolone susceptibility in Salmonella enterica serotypes in travelers returning from Southeast Asia. Emerg. Infect. Dis. 2001;7:996–1003
  17. Hanson ND, Moland ES, Hossain A, Neville SA, Gosbell IB, Thomson KS. Unusual Salmonella enterica serotype Typhimurium isolate producing CMY-7, SHV-9 and OXA-30 β-lactamases. J. Antimicrob. Chemother. 2002;49:1011–1014
  18. Heurtin-Le Corre C, Donnio P-Y, Perrin M, Travert M-F, Avril J-L. Increasing incidence and comparison of nalidixic acid-resistant Salmonella enterica subsp. enterica serotype Typhimurium isolates from humans and animals. J. Clin. Microbiol. 1999;37:266–269
  19. Horwitz MA, Pollard RA, Merson MH, Martin SM. A large outbreak of foodborne salmonellosis on the Navajo Nation India Reservation, epidemiology and secondary transmission. Am. J. Public Health. 1977;67:1071–1076
  20. Kristiansen MAM, Sandvang D, Rasmussen TB. In vivo development of quinolone resistance in Salmonella enterica serotype Typhimurium DT104. J. Clin. Microbiol. 2003;41:4462–4464
  21. Kruger T, Szabo D, Keddy KH, Deeley K, Marsh JW, Huger AM, et al. Infections with nontyphoidal Salmonella species producing TEM-63 or a novel TEM enzyme, TEM-131, in South Africa. Antimicrob. Agents Chemother. 2004;48:4263–4270
  22. Lee K, Yong D, Yum JH, Kim HH, Chong Y. Diversity of TEM-52 extended-spectrum β-lactamase–producing non-typhoidal Salmonella isolates in Korea. J. Antimicrob. Chemother. 2003;52:493–496
  23. Ling JM, Chan EW, Lam AW, Cheng AF. Mutations in topoisomerase genes of fluroqouinolone-resistant salmonellae in Hong Kong. Antimicrob. Agents Chemother. 2003;47:3567–3573
  24. Lyytikainen O, Koort J, Ward L, Schildt R, Ruutu P, Japisson E, et al. Molecular epidemiology of an outbreak caused by Salmonella enterica server Newport in Finland and the United Kingdom. Epidemiol. Infect. 2000;124:185–192
  25. Miriagou V, Filip R, Coman G, Tzouvelekis LS. Expanded-spectrum cephalosporin-resistant Salmonella strains in Romania. J. Clin. Microbiol. 2002;40:4334–4336
  26. Molbak K, Gerner-Smidt P, Wegener HC. Increasing quinolone resistance in Salmonella enterica serotype Enteritidis. Emerg. Infect. Dis. 2002;5:514–515
  27. Mulvey MR, Soule G, Boyd D, Demczuk W, Ahmed R. Multi-Provincial Salmonella Typhimurim Case Control Study Group. Characterization of the first extended-spectrum β-lactamase–producing Salmonella isolate identified in Canada. J. Clin. Microbiol. 2003;41:460–462
  28. Nakaya H, Yasuhara A, Yoshimura K, Oshihoi Y, Izumiya H, Watanabe H. Life-threatening infantile diarrhea from fluoroquinolone-resistant Salmonella enterica Typhimurium with mutations in both gyrA and parC. Emerg. Infect. Dis. 2003;9:255–257
  29. National Committee for Clinical Laboratory Standards . Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically: approved standard M7-A6. Wayne (PA): NCCLS; 2003;
  30. Navarro F, Perez-Trallero E, Marimon JM, Aliaga R, Gomariz M, Mirelis B. CMY-2–producing Salmonella enterica, Klebsiella pneumoniae, Klebsiella oxytoca, Proteus mirabilis and Escherichia coli strains isolated in Spain (October 1999–December 2000. J. Antimicrob. Chemother. 2001;48:383–389
  31. Oteo J, Aracil B, Alos JI, Gomez-Garces JL. High rate of resistance to nalidixic acid in Salmonella enterica: Its role as a marker of resistance to fluoroquinolones. Clin. Microbiol. Infect. 2000;6:265–282
  32. Piddock LJV, Griggs DJ, Hall MC, Jin YF. Ciprofloxacin resistance in clinical isolates of Salmonella typhimurium obtained from two patients. Antimicrob. Agents Chemother. 1993;37:662–666
  33. Pitout JD, Reisbig MD, Mulvey M, Chui L, Louie M, Crowe L, et al. Association between handling of pet treats and infection with Salmonella enterica serotype Newport expressing the AmpC β-lactamase, CMY-2. J. Clin. Microbiol. 2003;41:4578–4582
  34. Rankin SC, Aceto H, Cassidy J, Holt J, Young S, Love B, et al. Molecular characterization of cephalosporin-resistant Salmonella enterica serotype Newport isolates from animals in Pennsylvania. J. Clin. Microbiol. 2002;40:4679–4684
  35. Renuka K, Kapil A, Kabra SK, Wig N, Das BK, Prasad VVSP, et al. Reduced susceptibility to ciprofloxacin and gyrA gene mutation in North Indian strains of Salmonella enterica serotype Typhi and serotype Pharatyphi A. Microb. Drug Resist. 2004;10:146–153
  36. Ribot EM, Wierzba RK, Angulo FJ, Barret TJ. Salmonella enterica serotype Typhimurium DT104 isolated from humans, United States, 1985, 1990, and 1995. Emerg. Infect. Dis. 2002;8:387–391
  37. Rupali P, Abraham OC, Jesudason MV, John TJ, Zachariah A, Sivaram S, et al. Treatment failure in typhoid fever with ciprofloxacin susceptible Salmonella enterica serotype Typhi. Diagn. Microbiol. Infect. Dis. 2004;49:1–3
  38. Simarro E, Navarro F, Ruiz J, Miro E, Gomez J, Mirelis B. Salmonella enterica serovar Virchow with CTX-M–like β-lactamase in Spain. J. Clin. Microbiol. 2000;38:4676–4678
  39. Sivapalasingam S, Barrett E, Kimura A, Van Duyne S, De Witt W, Ying M, et al. A multistate outbreak of Salmonella enterica serotype Newport infection linked to mango consumption: Impact of water-dip disinfestations technology. Clin. Infect. Dis. 2003;37:1585–1590
  40. Stephen JM, Toleman MA, Walsh TR, Jones RN. SENTRY Program Participants Group. Salmonella bloodstream infections: Report from the SENTRY Antimicrobial Surveillance Program (1997–2001). Int. J. Antimicrob. Agents. 2003;22:395–405
  41. Tassios PT, Gazouli M, Tzelepi E, Milch H, Kozlova N, Sidorenko S, et al. Spread of a Salmonella typhimurium clone resistant to expanded-spectrum cephalosporins in three European countries. J. Clin. Microbiol. 1999;37:3774–3777
  42. Threlfall EJ, Ward LR, Rowe B. Resistance to ciprofloxacin in non-typhoidal salmonellas from humans in England and Wales: The current situation. Clin. Microbiol. Infect. 1999;5:130–134
  43. Threlfall EJ, Skinner JA, Ward LR. Detection of decreased in vitro susceptibility to ciprofloxacin in Salmonella enterica serotypes Typhi and Paratyphi A. J. Antimicrob. Chemother. 2001;48:740–741
  44. Vahaboglu H, Dodanli S, Eroglu C, Ozturk R, Soyletir G, Yildirim I, et al. Characterization of multiple-antibiotic-resistant Salmonella typhimurium strains: Molecular epidemiology of PER-1-producing isolates and evidence of nosocomial plasmid exchange by a clone. J. Clin. Microbiol. 1996;34:2942–2946
  45. Van Beneden CA, Keene WE, Strang RA, Werker DH, King AS, Mahon B, et al. Multinational outbreak of Salmonella enterica serotype Newport infection due to contaminated alfalfa sprouts. JAMA. 1999;281:158–162
  46. Villa L, Mammina C, Miriagou V, Tzouvelekis LS, Tassios PT, Nastasi A, et al. Multidrug and broad-spectrum cephalosporin resistance among Salmonella enterica serotype Enteritidis clinical isolates in southern Italy. J. Clin. Microbiol. 2002;40:2662–2665
  47. Yan JJ, Ko WC, Chiu CH, Tsai SH, Wu HM, Wu JJ. Emergence of ceftriaxone-resistant Salmonella isolates and rapid spread of plasmid-encoded CMY-2-like cephalosprinase, Taiwan. Emerg. Infect. Dis. 2003;9:323–328

PII: S0732-8893(05)00148-3

doi: 10.1016/j.diagmicrobio.2005.06.013

Diagnostic Microbiology & Infectious Disease
Volume 54, Issue 1 , Pages 13-21 , January 2006

Article Tools

* Image Usage & Resolution